Compensation looks quite different across the life sciences world. Pharma, biotech, and medical device or medtech companies each run on their own business models, carry different levels of risk, and sit at various stages of growth. Those differences shape how they pay people. In 2026 the industry continues to move carefully after several years of adjustment. Salary talks come up often for both job seekers and hiring managers.
Many things influence pay. Location, years of experience, the exact role, company size, and whether the work sits in research, clinical, regulatory, manufacturing, or commercial areas all matter. Base salary is only part of the picture. Bonuses, equity, benefits, and other perks add up differently depending on the sector. Here is a straightforward look at how compensation typically compares right now based on industry surveys and recruitment patterns.
Base Salary Patterns by Sector
Pharma
Large pharmaceutical companies usually provide the highest and steadiest base salaries. Because they have multiple approved products and reliable revenue, they can pay well across most functions. A scientist or clinical professional with eight to fifteen years of experience might see base pay starting in the low $150,000s and reaching well above $200,000 in major hubs. Director level and above roles often land in the $250,000 to $350,000 range or higher, especially in commercial or global work.
Pharma also tends to offer predictable bonuses, commonly 15% to 25% of base, linked to both company and individual results. Benefits packages tend to be solid with good retirement matching and health coverage.
Biotech
Biotech pay shows more variation. Early stage or venture backed companies frequently offer lower base salaries than big pharma. They try to balance that with meaningful equity grants. A scientist or associate director in a clinical stage biotech might earn base pay between $130,000 and $180,000 in expensive cities. Specialized roles in cell and gene therapy or those involving data and AI can push higher.
Later stage or public biotechs with better cash reserves can match pharma more closely on base while still providing equity upside. The catch is risk. Bonuses may be smaller or less reliable. Total compensation can change a lot depending on funding success, clinical results, or stock movement.
MedTech
Medtech compensation usually sits between the other two sectors. Engineers, clinical specialists, or quality professionals with similar experience often see base salaries ranging from $140,000 to $190,000. Roles with a commercial or sales focus can include larger variable pay through commissions.
Medtech pay often rewards practical execution and product launches more than pure scientific discovery. Equity tends to be present but usually smaller than what early biotech offers. Overall stability falls somewhere between the predictability of big pharma and the higher risk of biotech.
What Drives the Differences
Risk and stability play a big role. Pharma provides the most consistent pay because of diversified products and steady cash flow. Biotech offers the greatest potential upside through equity but also carries more downside if programs stall or funding dries up. Medtech strikes more of a balance with emphasis on getting products to market and generating revenue from existing lines.
Equity stands out as a major factor in biotech. Early companies may grant generous stock options or restricted units that could become very valuable if the company succeeds or gets acquired. Pharma equity is generally more modest and tied to overall company performance. Medtech grants tend to be moderate.
Location continues to matter a lot. Pay in Boston, the San Francisco Bay Area, and San Diego runs noticeably higher across all sectors to offset living costs. Roles in other regions or emerging hubs may come with 15% to 25% percent lower base pay. Sometimes total compensation stays competitive when lower taxes or better quality of life are taken into account.
Certain functions show wider gaps. Discovery scientists and early clinical roles often receive stronger equity emphasis in biotech. Manufacturing, quality, and regulatory positions command solid base pay in all three sectors. Medtech and pharma sometimes lead in technical operations pay. Commercial and sales jobs in medtech and pharma can include big variable components that push total cash compensation well beyond base salary.
The Picture in 2026
Salary offers remain competitive but careful this year. After recent workforce changes, companies watch spending closely. Sign on bonuses and relocation help attract talent in tight areas such as cell and gene therapy manufacturing, advanced regulatory experience, or roles that blend science with digital skills.
Job candidates look at the full package more than ever. They weigh base salary against equity potential, bonus structure, work life balance, and future growth. Professionals with scarce skills, like CMC expertise or experience with antibody drug conjugates, often hold more negotiating power when comparing offers across sectors.
For hiring teams, it helps to set realistic expectations. Trying to hire for an early biotech with only pharma level base pay and little equity rarely succeeds. Expecting biotech style risk tolerance in a medtech environment can also create mismatches.
These patterns come from aggregated survey data and day to day recruitment observations. Actual offers always depend on the specific company, its pipeline strength, and the candidate background. Numbers shift over time with market conditions.
In the end many professionals choose their path based on more than money alone. Some value the stability and clear career steps in pharma. Others chase the scientific intensity and possible financial upside in biotech. A good number find satisfaction in medtech where they can work on real products that reach patients while keeping reasonable balance in their lives.
Understanding how pay typically breaks down across these three areas can help both sides make clearer decisions in a talent market that remains selective and complex.
If you would like a more detailed compensation report for an upcoming project, please contact us today.
Leading talent partner delivering precise recruiting and workforce solutions to biotech, pharma, and medical device organizations